April 19th 2024
The American College of Physicians released new recommendations for the management of type 2 diabetes with inadequate glycemic control using metformin or other first-line therapies.
FDA Approves Proclaim XR Spinal Cord Stimulation for Painful Diabetic Peripheral Neuropathy
Abbott's Proclaim XR spinal cord stimulation system allows patients with painful diabetic peripheral neuropathy to improve quality of life using a system that is easily incorporated into their everyday lives.
20-Year Study Finds Cancer Mortality On The Rise People with Type 2 Diabetes
January 25th 2023An analysis of 2 decades worth of data from the Clinical Practice Research Datalink suggests all-cause mortality rates in type 2 diabetes have decreased but sheds light on upward trends in mortality from multiple different forms of cancer, including pancreatic, liver, and lung cancer, particularly among older patients.
Bexagliflozin (Brenzavvy) Receives FDA Approval for Type 2 Diabetes in Adults
January 23rd 2023Announced on January 23, the US FDA's approval of bexagliflozin (Brenzavvy) was awarded to TheracosBio and indicates the SGLT2 inhibitor for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Diabetes Dialogue: ADCES DTC 22, with Jennifer Okemah, RD, and Gary Scheiner, MS
January 21st 2023In their final episode from the ADCES 2nd Annual Diabetes Technology Conference, our hosts are joined by Gary Scheiner, MS, and Jennifer Okemah, RD, to discuss their businesses, a glimpse into their personal journeys into becoming diabetes care and education specialists, and how they have seen their role in improving care transform in recent years.
Impact of Traditional Stroke Risk Factors on Stroke Risk Lessens Over Time, Study Finds
January 19th 2023An analysis of patient data from the REGARDS cohort suggests the increase in relative risk observed with traditional risk factors, such as hypertension and diabetes, on risk of stroke decreases as patients age, but investigators point out this does not diminish the importance of addressing these risk factors.
Anti-VEGF Use for Diabetic Eye Diseases Increased 200% in Last Decade
January 16th 2023An analysis of a commercial claims database offers insight into the increase in vision-threatening eye disease among people with diabetes aged younger than 65 years from 2009-2018, with results also detailing trends in anti-VEGF therapy during the same period.
Diabetes Dialogue: The Prospect of a Bionic Pancreas, with Steven Russell, MD, PhD
January 14th 2023In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Steven Russell, MD, PhD, the chief medical officer of Beta Bionics, for a discussion around his journey to becoming CMO as well as a deep dive into the iLet Bionic Pancreas and its potential in diabetes management.
FDA Updates Label for Oral Semaglutide, Making Agent a First-Line Therapy in Type 2 Diabetes
January 13th 2023Announced by Novo Nordisk on January 12, the label update from the FDA removes a previous indication stating oral semaglutide (Rybelsus) should not be used as an initial therapy, which clears the way for the agent to be used as a first-line therapy in type 2 diabetes.
Rates of Type 1, Type 2 Diabetes Expected to Balloon in US by 2060
January 12th 2023Using data from the SEARCH for Diabetes in Youth study, a new analysis suggests rates of type 1 diabetes in youth may increase by 65% between now and 2060, while rates of type 2 diabetes could increase more than 600% during that same period if left unchecked.
Presence of Diabetes Linked to Greater Likelihood of Frozen Shoulder
January 10th 2023Eight studies provided evidence to suggest the relationship between diabetes and the onset of frozen shoulder, but more high-quality cohort studies may be necessary to better understand the nature of the relationship.
SGLT2 Inhibitors Can Aid Weight Loss, Reduce Fat Mass in People with Type 2 Diabetes
January 7th 2023Using data from 18 trials with more than 1400 participants, a systematic review and meta-analysis offer clinicians an overview of the effects of SGLT2 inhibitor use on body composition in people with type 2 diabetes.
SGLT2 Inhibitors Can Reduce Cardiometabolic Risk in People with Diabetes Using Metformin
January 6th 2023Using data from more than 55,000 people with diabetes using metformin is providing new insight into the apparent reductions in risk of negative cardiovascular and renal outcomes as well as all-cause mortality with use of SGLT2 inhibitors.
Optimal Glycemic Control Could Slow Biological Aging in Adults with Type 2 Diabetes
January 4th 2023Exploratory analyses of data from the Look AHEAD trial suggest maintaining an HbA1c level of 7% or less was associated with smaller increases in frailty index over the 8-year study period when compared to their counterparts with an HbA1c level of 8% or greater.